CCDC198

Across TCGA pan-cancer cohorts, CCDC198 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated CCDC198 data layer compared with 21 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher CCDC198 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CCDC198 expression acts as an unfavorable survival marker.

BLCA, LIHC, and STAD are the cancer types where CCDC198 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	IV	0.090	0.605	<.001	12	view →
LIHC	DFS	Median	All	0.044	0.553	<.001	12	view →
STAD	OS	Median	III,IV	0.184	0.641	.011	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

CCDC198–BLCA (OS)

Open the BLCA breakdown →